InvestorsHub Logo
Followers 37
Posts 564
Boards Moderated 0
Alias Born 01/29/2015

Re: None

Thursday, 04/20/2017 2:57:18 PM

Thursday, April 20, 2017 2:57:18 PM

Post# of 118342
On the optimization.

"It is gratifying that we have expanded our small molecule portfolio in such a way that we have reduced risk in the development program so early in the process," says David Koos, Ph.D., CEO and Chairman of Regen. "With ChemDiv, Inc. as our key partner, we are moving at a rapid pace towards our goal of having clinical candidate drugs in fourth quarter of 2017."

The reason for the greed is obvious. Regen will have a major partner before this goes much further. I believe the biggest Pharma in the world (Novartis) is behind its competitors in the Immunology field and this will help them catch up. IMO of coarse.

Best regards!
Schuller.